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BACKGROUND: Dengue virus (DENV) is an arbovirus
primarily transmitted through mosquito bite; however, DENV transfusion-transmitted infections (TTIs) have been reported and asymptomatic DENV RNA-positive blood donors have been identified in endemic countries. DENV is considered a high-risk pathogen for blood safety. One of the mitigation strategies to prevent arbovirus TTIs is pathogen inactivation. In this study we demonstrate that the amustaline and glutathione (S-303/ GSH) treatment previously found effective against Zika virus in red blood cells (RBCs) is also effective in inactivating DENV.
STUDY DESIGN AND METHODS: Red blood cells
were spiked with high levels of DENV. Viral RNA loads and infectious titers were measured in the untreated control and before and after pathogen inactivation treatment of RBC samples. DENV infectivity was also assessed over five successive cell culture passages to detect any potential residual replicative virus.
RESULTS:
The mean 6 SD DENV titer in RBCs before inactivation was 6.61 6 0.19 log 50% tissue culture infectious dose (TCID 50 )/mL and the mean viral RNA load was 8.42 log genome equivalents/mL. No replicative DENV was detected either immediately after completion of treatment using S-303/GSH or after cell culture passages.
CONCLUSION: Treatment using S-303/GSH inactivated high levels of DENV in RBCs to the limit of detection. In combination with previous studies showing the effective inactivation of DENV in plasma and platelets using the licensed amotosalen/UVA system, this study demonstrates that high levels of DENV can be inactivated in all blood components.
T he four serotypes of Dengue virus (DENV-1 to DENV-4) are single-stranded RNA arthropodborne viruses (arboviruses) belonging to the genus Flavivirus, family Flaviviridae.
1 Immunity against DENV is serotype specific. 1 The clinical spectrum of DENV infections ranges from mild symptoms (including sudden high fever, headache, rash, nausea, myalgia, and arthralgia) to severe complications (including plasma leakage, bleeding, and severe organ involvement). 2 Additionally the severity of dengue symptoms may be increased upon reinfection with a different serotype through antibody-dependent enhancement, which becomes particularly problematic in areas where multiple serotypes of DENV circulate at the same time or circulate sequentially. 3 Of all the arboviruses, DENV has the highest global burden, with an incidence of approximately 390 million infections per year. 4 It is estimated that 3.9 billion people living in 128 countries are at risk for infection.
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DENV is transmitted by Aedes species mosquitoes, mainly Aedes aegypti and, to a lesser extent, Aedes albopictus; however, non-vector-borne transmission of DENV has been reported via blood transfusion, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 18, 19 Additionally, confirmatory assays to confirm DENV TTIs are often lacking in most endemic countries, and dengue can be misdiagnosed as a noninfectious adverse posttransfusion reaction, an existing underlying condition, a disease resulting from an infection by another pathogen, or even a vectorial transmission to the blood transfusion recipient.
On the blood donor side, deferral based on clinical presentation and postdonation symptom reporting may not identify asymptomatic viremic donors and is therefore not sensitive enough to prevent DENV TTIs. 20 Discontinuing blood collection in endemic countries and importing blood components from nonendemic areas is not practical and may be impossible in remote areas. In the absence of a commercially available licensed DENV nucleic acid testing (NAT) assay, deferral based on residence or travel to endemic areas may result in significant loss of blood donors with negative impact on blood product availability. Conversely, pathogen reduction technologies (PRTs) used for the treatment of blood components can offer an interesting alternative approach to mitigate the risk of TTIs. The promise of such systems is the ability to reduce the infectivity of a broad range of pathogens, including bacteria, protozoa, and viruses. 21 Licensed PRT systems are available in many areas, including countries that recognize CE accreditation (INTERCEPT, Theraflex, Mirasol) and the United States (INTERCEPT, Octaplas) for inactivation of plasma and PLTs, but no licensed system is yet available for the treatment of RBCs. 22 These PRTs have been shown to reduce DENV infectivity with various degrees of efficacy. [23] [24] [25] The technology using amotosalen and ultraviolet A light (amotosalen/UVA) was previously shown to inactivate high levels of DENV titers in plasma 23, 24 and PLTs. 25, 26 Inactivation to the limit of detection of the assay was found equally effective for all four DENV serotypes. 23, 26 Technology for the treatment of RBCs and whole blood using chemical and photochemical processes has been described. 27 The INTERCEPT Blood 22 The INTER-CEPT Blood System for RBCs uses a chemical treatment targeted to nucleic acids with the small-molecule amustaline (S-303) that forms covalent adducts with nucleic acids resulting in the inactivation of pathogens. S-303 is a reactive modular compound that is designed to react quickly and then decompose by hydrolysis to the nonreactive compound S-300 (Fig. 1) . It is formulated in the presence of the natural tripeptide glutathione (GSH) to quench undesirable side reactions. In this new study, we investigated the use of S-303/GSH to inactivate high levels of DENV in RBCs. RBCs were spiked with DENV, and viral infectivity levels and RNA loads were determined before and after S-303/GSH treatment, in accordance with the recommendations for evaluation of pathogen reduction efficacy. 28 
MATERIALS AND METHODS
The schematic flow diagram of the experiment is shown in Fig. 2 . RBCs were spiked with DENV-1, and viral RNA loads and infectious titers were determined in RBCs samples collected before (preinactivation and noninactivated samples) and after treatment with saline (mock-treated control) or S-303/GSH (postinactivation samples). Samples were used for inoculation onto African green monkey kidney (Vero) cell cultures; five successive passages of 4 to 5 days each were performed by inoculation of the previous passage supernatant onto fresh Vero cells to amplify any trace of replicative DENV.
Blood products
French Polynesia is a highly endemic area for DENV, with more than 80% of the blood donors having specific antibodies against DENV. 29 To reduce the risk of DENV antibodies in blood products collected in French Polynesia, whole blood (500 mL) collected with CPD was acquired from a nonendemic US region, Bonfils Blood Center. 
Virus
The DENV-1 strain (PF08/080108-88) isolated from a French Polynesian patient was propagated on Vero cells at 378C in a 5% CO 2 atmosphere . Four DENV concentrates were produced using centrifugal filter devices (Centricon Plus-70, Millipore) as previously described and stored at 2808C with fetal bovine serum (Life Technologies) added at a 1:5 dilution.
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Spiking of RBCs and inactivation process
The INTERCEPT Blood System for RBCs includes an S-303 vial, a GSH vial, a trifurcated set with two 0.2-mm filters, and a processing set with three containers: a mixing bag containing a proprietary processing solution, an incubation bag, and a storage bag containing SAG-M (shown in Fig. 3 ). Four RBC units were spiked with concentrated DENV-1 stock. Units 1, 2, and 3 were treated with S-303/ GSH using the INTERCEPT Blood System for RBCs as previously described, 22 while Unit 4 was "mock treated" with an equal volume of saline in lieu of S-303/GSH. Two control samples were removed from each untreated test unit (UT) after the addition of GSH, but before addition of S-303. For the mock-treated unit, the control was removed after the addition of saline, simulating GSH treatment, but before the second saline addition to mimic S-303 treatment. The first control sample was frozen immediately after collection (UT0), while the second was incubated at room temperature for 20 hours (UT20) alongside the treated test units. A treatment solution exchange step was performed at approximately 20 hours posttreatment and postinactivation test samples (TT20h) were collected from treated Units 1, 2, and 3 and mock-treated Unit 4.
Detection of replicative DENV and DENV infectivity titration
Detection of replicative DENV and viral titration were performed as previously described. 22 For the detection of replicative DENV, RBC samples (preinactivation, noninactivated, and postinactivation) were inoculated in triplicate on Vero cells in 24-well plates and five successive passages were performed. The presence of infectious DENV was detected by indirect immunofluorescence assay (IFA) using Dengue Type 1 hyperimmune ascitic fluid IA1 (National Institute of Allergy and Infectious Diseases) diluted 1:100 in phosphate-buffered saline (PBS). For DENV titration, RBC samples were serially diluted and inoculated on Vero cells in 96-well plates. Infectious DENV-1 was detected by IFA using antibodies IA1 diluted 1:100 in PBS. Wells with infectious virus were counted for each dilution and viral titers were expressed as TCID 50 / mL using the method of Reed and Muench. 31 All quantifications were performed in triplicate.
DENV RNA quantification
For all RBC samples and cell culture supernatants, DENV RNA extraction was performed on 200 mL using an extraction system (QIAcube, Qiagen), and real-time reverse transcription polymerase chain reaction (RT-PCR) was performed using a thermocycler (CFX96, Bio-Rad), as previously described. 32, 33 A standard curve using serial dilutions of a DENV RNA synthetic transcript with a known concentration was included within the RT-PCR run to estimate the copy number in the samples. 24 Results are expressed in geq/mL.
RESULTS
Detection of replicative DENV and DENV infectivity titration
For Units 1 to 3, the mean 6 SD DENV infectious titer was 6.61 6 0.19 log TCID 50 /mL in preinactivation samples (UT0) and 5.46 6 0.2 log TCID 50 /mL in noninactivated samples (UT20h; Table 1 ). Immediately after inactivation, no replicative DENV was detected in any of Units 1 to 3 postinactivation samples (TT20h), while the culture of Units 1 to 3 preinactivation (UT0) and noninactivated (UT20h) control samples, as well as Unit 4 pretreatment (UT0), nontreated (UT20h), and mock-treated (TT20h) samples produced replicative viruses during successive passages, as demonstrated with IFA. For Unit 4, the reduction observed for the mock-treated sample (reduction from 6.92 to 3.73 log TCID 50 /mL) is consistent with the dilution of the virus during the exchange process, if one assumes an even distribution in the total volume during the dilution and volume exchange process.
DENV RNA quantification
For Units 1 to 3, viral RNA loads averaged 8.42 6 0.04 log geq/mL in preinactivation samples (UT0) and 8.51 6 0.17 log geq/mL in noninactivated samples (UT20h; Table 2 ). Immediately after treatment (Units 1-3; TT20h), DENV RNA loads averaged 5.86 6 0.08 log geq/mL. The detection of DENV RNA after treatment is likely due to the presence of inactivated input virus that was unable to replicate, but with conserved nucleic acid sequences that could be amplified. This is supported by the fact that after the first inoculation of treated test samples (Units 1-3; TT20h) onto Vero cells, viral RNA was not detected, except for a very low level in the supernatant of Unit 1 (1.53 log geq/ mL). All subsequent passages resulted in no detectable DENV RNA, indicating that the RNA measured after the first inoculation of treated test sample from Unit 1 was residual input DENV and was not produced by virus capable of continued replication. In contrast, both preinactivation (UT0) and noninactivated (UT20h) control 12, 14, 38 and Madeira, Spain (1.5% in 2012). 39 In
Brazil, it was estimated that DENV RNA can be detected by NAT for approximately 9 days in presymptomatic viremic patients. 7 Therefore, there is a high risk for DENV TTIs in endemic areas. Proving arbovirus TTIs in endemic areas is challenging because the entire population is also exposed to infectious mosquito bites in the community.
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DENV TTIs also likely go underrecognized and/or underreported as surveillance systems capable of detection and confirmation cases are not in routine use in most DENVendemic areas. 41 However, DENV TTIs have been reported after the transfusion of plasma, PLT, and RBC components and DENV infectivity was shown to persist for the duration of PLT and RBC storage period. 42 It is worth noting that, while DENV was identified as one of the highpriority infectious agents with actual or potential risk for transfusion transmission, 43, 44 there is no licensed DENV NAT assay commercially available yet for the screening of blood donations. 45 The availability of licensed PRT systems that allow treatment of all blood products would be of great interest. Using the same protocol as previously described to demonstrate the efficacy of INTERCEPT to inactivate DENV in plasma, 24 and ZIKV in plasma, PLTs, and RBCs, 22, 46, 47 we demonstrate in this study that treatment of RBCs using S-303/GSH results in the inactivation to the limit of detection (>6.61 log) of DENV-1 infectivity corresponding to 8.42 log DENV-1 geq/mL. We report that no replicative DENV could be detected either immediately after treatment completion or after five passages on Vero cell cultures. While DENV RNA was still amplifiable immediately after inactivation, as previously described for the inactivation of ZIKV in RBCs, 22 no DENV RNA was detected from the first passage on (except for Unit 1). This suggested that there were no remaining infectious DENV particles immediately after completion of the treatment. This was further confirmed by the lack of detection of replicative DENV particles from the first passage after treatment. The detected low level of DENV RNA after the first passage of the treated sample from Unit 1 in the absence of detected infectivity was likely due to residual RNA left behind after incomplete wash of the cell monolayer in one of the cell culture plate wells. Indeed the lack of detection of DENV RNA in subsequent cell culture passages confirmed this hypothesis. The level of DENV reduction achieved in RBCs using the S-303/GSH treatment exceeded 8 log geq/mL and meets the expectations of the Food and Drug Administration (FDA), who recommends that PRTs achieve a 6 to 10 log geq/mL pathogen load reduction. 28 The FDA recommendation seems justified for DENV in the light of the high DENV RNA loads (up to 10 9 geq/mL) measured in blood from asymptomatic donors.
14 In our study the INTERCEPT Blood System for RBCs inactivated 8.42 log geq/mL or 2.6 3 10 9 RNA copies/mL.
Therefore, the S-303/GSH system can inactivate RNA loads comparable to the highest DENV RNA load reported in asymptomatic blood donors. 14 In this study, the RNA load to infectivity ratio for DENV-1 was approximately 2 log, while it was about 4 log for the study conducted in plasma with amotosalen/UVA. 24 Similar ratios of 2 and 4 log differences between geq and infectious virus were observed for ZIKV in RBCs and plasma, respectively.
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Different infectivity/RNA copy ratios in RBCs versus plasma may be due to the different extraction methods used for RBCs and plasma, while the RT-PCR assay may in addition be inhibited by contamination of the extracted RNA with hemoglobin or its degradation products. 48 In DENV-endemic areas serotype switch or introduction of a new serotype is of concern, as it places the population that is not immune against the new serotype at increased risk for the development of severe DENV infections, while the part of the population that has been exposed to other serotypes may face complications through antibody-dependent enhancement. A multiplexed NAT assay that can detect DENV, ZIKV, and CHIKV has been approved by the FDA for diagnostic purposes, 49 but there is no approved multiplex assay for blood donor screening. Additionally, there is a commercial dengue NAT assay (by Grifols/Hologic) that is CE-marked for use in donor screening. The assay is able to detect all four serotypes, but has had limited adoption. Blood screening companies located in nonendemic areas may be reluctant to develop NAT assays for neglected pathogens and, in endemic areas, DENV is less of a priority when access to the most sensitive HIV NAT blood screening assays are also lacking. 45 In DENV-endemic areas, physicians have reported that severe clinical outcomes are observed in Broad-spectrum robust PRT represents an attractive alternative to blood screening using individual or even multiplex NAT assays in areas where arboviruses are often cocirculating and is a proactive strategy that seems more sustainable as pathogens emerge or reemerge. [51] [52] [53] [54] [55] In addition for DENV, due to its mode of action, the PRT system using amotosalen/UVA was shown efficient at inactivating DENV, regardless of the serotype. 23 The same can be assumed to hold true for the S-303/GSH for RBCs. Indeed, the PRT system using S-303/GSH has the same mode of action ( Fig. 1 ) as amotosalen/UVA; both systems selectively target nucleic acids, forming adducts and crosslinks that prevent nucleic acid replication or transcription. Therefore, S-303/GSH, which is shown in this study to efficiently inactivate DENV-1, should be efficient at inactivating all three other DENVs. The previous studies (Table 3 ) demonstrating more than 5.61 log TCID 50 /mL and more than 5.3 log plaqueforming units (PFU)/mL DENV reduction in plasma and PLTs using amotosalen/UVA, respectively, and this study reporting more than 6.61 log TCID 50 /mL DENV reduction in RBCs using S-303/GSH indicate that DENV can be efficiently inactivated to the limit of detection in all blood components using the INTERCEPT Blood Systems. The findings in this study could be used by regulatory authorities to guide mitigation strategies needed throughout the world. Indeed, in 2016, DENV caused more than 2.3 million infections in the Americas, 375,000 infections in the Western Pacific region, and outbreaks in Africa. 2 In the first trimester of 2017, more than 50,000 infections were reported in the Americas, while multiple serotypes are reported to be cocirculating in most of Latin America and Caribbean countries. The development of any system for inactivation of pathogens in RBCs needs to address the potential shortterm and long-term effects on patients that receive RBC transfusion for acute and chronic anemia. The safety and efficacy of the pathogen-inactivated RBCs need to be evaluated in preclinical in vitro and in vivo studies, as well as well-controlled clinical trials.
The INTERCEPT Blood System for RBCs has been extensively studied in both in vitro and in vivo animal models and culture systems and optimized for safety and efficacy. Toxicology studies conducted according to the International Committee for Harmonization guidelines have characterized both for the treated RBCs and the final reaction products. 56 In a Phase II clinical study, S-303/ The work performed to date has addressed concerns about the ability of RBCs to transport oxygen and replace conventional RBCs in the areas of acute and chronic anemia. In addition, potential neoantigenicity concerns as the ones observed in past generations of the system were systematically evaluated in vitro and in vivo before the design of the current process and with population surveys for the presence of preexisting antibodies, as well as during the clinical studies. 60 No evidence has been found to date for such an effect. The effectiveness of the S-303/GSH treatment against viruses, bacteria, and parasites as well as T cells 61, 62 has been demonstrated, with both in vitro cell culture models and animal infectivity models. For example in the Syrian hamster model for Babesia microti, 63 treatment of RBCs that had high parasitemia loads with S-303/GSH has been shown to prevent infection to animals. The results consistently show that the efficacy observed with the in vitro viral culture systems, which use laboratory-propagated pathogens that may differ from those found in nature, correspond to the elimination of infectivity in the animal models.
As is the case for the amotosalen/UVA system for the treatment of PLTs and plasma, the best evidence for the prevention of infection after use of the system for the inactivation of pathogens in RBCs may come from routine use. The use of amotosalen/UVA in Europe for the past 10 years resulted in a significant decrease in the rate of TTIs in France, Switzerland, and Belgium, 64 without a concomitant increase of component use. In addition, the use in routine achieved, shows that such systems are compatible with the current manufacturing of blood components with manageable logistics, when applied to the level of a blood center, 65 a region, 66 or a country. 67 The use of PRT in dengue endemic areas is compelling as it can be proactively implemented to safeguard the blood supply against all four DENV serotypes 23 as well as other cocirculating pathogens, like ZIKV. 22 The primary limitation to universal adoption of PRT is that, unlike for PLTs and plasma components, a licensed system is not yet available for RBCs. As RBCs are the most frequently transfused blood components, there is an urgent need to have a PRT approved for the treatment of RBCs.
